SV2011003895A - Derivados de carbamatos de alquil-heterociclos,su preparacion y su aplicación en terapeutica - Google Patents

Derivados de carbamatos de alquil-heterociclos,su preparacion y su aplicación en terapeutica

Info

Publication number
SV2011003895A
SV2011003895A SV2011003895A SV2011003895A SV2011003895A SV 2011003895 A SV2011003895 A SV 2011003895A SV 2011003895 A SV2011003895 A SV 2011003895A SV 2011003895 A SV2011003895 A SV 2011003895A SV 2011003895 A SV2011003895 A SV 2011003895A
Authority
SV
El Salvador
Prior art keywords
group
rent
therapeutics
trifluorometilo
atom
Prior art date
Application number
SV2011003895A
Other languages
English (en)
Inventor
Ahmed Abouabdellah
Nathalie Chereze
Aude Fayol
Mourad Saady
Philippe Yaiche
Julien Vache
Corinne Veronique
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40852115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2011003895(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of SV2011003895A publication Critical patent/SV2011003895A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)

Abstract

COMPUESTO QUE CORRESPONDE A LA FÓRMULA GENERAL (I): EN LA QUE R2 REPRESENTA UN ÁTOMO DE HIDRÓGENO, DE FLÚOR O UN GRUPO HIDROXILO, CIANO, TRIFLUOROMETILO, ALQUILO-C1- 6, ALCOXI-C1-6, NR8R9; N REPRESENTA UN NÚMERO ENTERO IGUAL A 1, 2 Ó 3 Y M REPRESENTA UN NÚMERO ENTERO IGUAL A 1 Ó 2; A REPRESENTA UN ENLACE COVALENTE O UN GRUPO ALQUI¡ENO-C1-8 ; R1 REPRESENTA UN GRUPO FENILO, PIRIDINILO, PIRIDACINILO, PIRIMIDINILO, PIRACINILO, TRIACINILO, NAFTALENILO, QUINOLINILO, ISOQUINOLINILO, FTALACINILO, QUINAZOLINILO, QUINOXALINILO, CINOLINILO, NAFTIRIDINILO, ESTANDO ESTE GRUPO SUSTITUIDO OPCIONALMENTE; R3 REPRESENTA UN ÁTOMO DE HIDRÓGENO, DE FLÚOR, UN GRUPO ALQUILO-C1-6 O UN GRUPO TRIFLUOROMETILO ; R4 REPRESENTA UN GRUPO ELEGIDO ENTRE UN FURANILO, PIRROLILO, TIENILO, ISOTIAZOLILO, OXAZOLILO, ISOXAZOLILO, PIRAZOLILO, OXADIAZOLILO, TIADIAZOLILO, IMIDAZOL, TRIAZOLILO, TETRAZOLILO, OXAZOLONA, OXAZOLIDINONA, ISOXAZOLONA, ISOXAZOLIDINONA, ISOTIAZOLONA, ISOTIAZOLIDINONA, IMIDAZOLONA, IMIDAZOLIDINONA, PIRAZOLONA, PIRAZOLIDINONA, OXADIAZOLONA, TIADIAZOLONA, TRIAZOLONA, ESTANDO ESTE GRUPO SUSTITUIDO OPCIONALMENTE; EN EL ESTADO DE BASE O DE SAL DE ADICIÓN A UN ÁCIDO. USO EN TERAPÉUTICA
SV2011003895A 2008-11-14 2011-05-05 Derivados de carbamatos de alquil-heterociclos,su preparacion y su aplicación en terapeutica SV2011003895A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0806371A FR2938537B1 (fr) 2008-11-14 2008-11-14 Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
SV2011003895A true SV2011003895A (es) 2011-08-15

Family

ID=40852115

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003895A SV2011003895A (es) 2008-11-14 2011-05-05 Derivados de carbamatos de alquil-heterociclos,su preparacion y su aplicación en terapeutica

Country Status (27)

Country Link
US (1) US8716289B2 (es)
EP (1) EP2356108B1 (es)
JP (1) JP5560287B2 (es)
KR (1) KR20110083743A (es)
CN (1) CN102216291B (es)
AR (1) AR074119A1 (es)
AU (1) AU2009315448B2 (es)
BR (1) BRPI0921057A2 (es)
CA (1) CA2743558C (es)
CL (1) CL2011001122A1 (es)
CO (1) CO6331472A2 (es)
CR (1) CR20110246A (es)
EA (1) EA019742B1 (es)
EC (1) ECSP11011040A (es)
FR (1) FR2938537B1 (es)
IL (1) IL212830A (es)
MA (1) MA32884B1 (es)
MX (1) MX2011005124A (es)
NI (1) NI201100095A (es)
NZ (1) NZ592740A (es)
PA (1) PA8848901A1 (es)
PE (1) PE20120217A1 (es)
SV (1) SV2011003895A (es)
TW (1) TWI462919B (es)
UY (1) UY32246A (es)
WO (1) WO2010055267A1 (es)
ZA (1) ZA201103516B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934265B1 (fr) * 2008-07-23 2010-07-30 Sanofi Aventis Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
WO2016017467A1 (ja) * 2014-07-28 2016-02-04 住友化学株式会社 アミド化合物及びその有害節足動物防除用途
CN111171315B (zh) * 2020-02-25 2021-08-17 常熟理工学院 一种结晶性n-取代聚硫代氨基甲酸酯及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050088992A (ko) * 2002-10-07 2005-09-07 더 리전트 오브 더 유니버시티 오브 캘리포니아 아난드아미드 가수분해 차단을 통한 불안감의 조절
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
PL1732892T3 (pl) 2004-03-26 2009-03-31 Hoffmann La Roche Tetrahydrokarbazole i pochodne
SE0401656D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
RU2391340C2 (ru) * 2004-08-11 2010-06-10 Киорин Фармасьютикал Ко., Лтд. Новое циклическое производное аминобензойной кислоты
US20070078135A1 (en) * 2005-04-18 2007-04-05 Neurogen Corporation Substituted heteroaryl CB1 antagonists
GB0510140D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
WO2007146761A2 (en) * 2006-06-12 2007-12-21 Neurogen Corporation Diaryl pyrimidinones and related compounds
EP2220068B1 (en) 2007-11-16 2016-01-27 Incyte Holdings Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
FR2934265B1 (fr) 2008-07-23 2010-07-30 Sanofi Aventis Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
FR2938537A1 (fr) 2010-05-21
CN102216291A (zh) 2011-10-12
UY32246A (es) 2010-06-30
US8716289B2 (en) 2014-05-06
AU2009315448A1 (en) 2010-05-20
TW201026692A (en) 2010-07-16
NI201100095A (es) 2011-12-14
EP2356108A1 (fr) 2011-08-17
NZ592740A (en) 2013-03-28
BRPI0921057A2 (pt) 2018-10-16
WO2010055267A1 (fr) 2010-05-20
IL212830A (en) 2014-11-30
AR074119A1 (es) 2010-12-22
CA2743558C (fr) 2017-02-14
MA32884B1 (fr) 2011-12-01
MX2011005124A (es) 2011-05-30
PE20120217A1 (es) 2012-03-12
EP2356108B1 (fr) 2014-10-15
IL212830A0 (en) 2011-07-31
JP5560287B2 (ja) 2014-07-23
EA019742B1 (ru) 2014-05-30
CR20110246A (es) 2012-06-15
TWI462919B (zh) 2014-12-01
JP2012508785A (ja) 2012-04-12
PA8848901A1 (es) 2010-06-28
AU2009315448B2 (en) 2015-07-16
CN102216291B (zh) 2016-08-03
CL2011001122A1 (es) 2011-09-16
KR20110083743A (ko) 2011-07-20
US20120015950A1 (en) 2012-01-19
EA201170686A1 (ru) 2011-12-30
ZA201103516B (en) 2012-07-25
CO6331472A2 (es) 2011-10-20
CA2743558A1 (fr) 2010-05-20
ECSP11011040A (es) 2011-06-30
FR2938537B1 (fr) 2012-10-26

Similar Documents

Publication Publication Date Title
SV2011003895A (es) Derivados de carbamatos de alquil-heterociclos,su preparacion y su aplicación en terapeutica
ES2560003T3 (es) Inhibidores de la serina proteasa de VHC derivados de prolina macrocíclica
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
UY31736A (es) Derivados sustituidos de pirazol y su uso
ATE439349T1 (de) Cyclische anilinopyridinotriazine als gsk-3- inhibitoren
HRP20120830T1 (hr) Imidazolkarboksamidi
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
AR076562A1 (es) Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica
CY1109883T1 (el) Υδατικα συγκεντρωματα δραστικων ουσιων με ζιζανιοκτονα δραση
RS50553B (sr) Derivati imidazola kao tafia-inhibitori
MX2010007019A (es) Compuestos de bencimidazol.
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica
EA200901234A1 (ru) 4-(4-трифторметил-3-тиобензоил)пиразолы и их применение в качестве гербицидов
AR083147A1 (es) Composicion pesticida y su uso
MX2010006446A (es) Nuevos derivados de diazeniodiolato, procedimiento para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ES2541401T3 (es) Nuevos derivados de isoquinolina disustituidos en 6,7 y su uso
WO2009025265A1 (ja) ピペラジン誘導体
WO2009021957A3 (en) Tricyclic heterocyclic compounds as gaba a modulators
CY1114378T1 (el) Μεθοδος χρησιμοποιησης συνδυασμου παραγωγου βενζοφαινονης ή αλατος αυτου και ανοσοκατασταλτικου παραγοντα, και φαρμακευτικη συνθεση που περιλαμβανει αυτα τα συστατικα
CO5690555A2 (es) Preparacion farmaceutica solida
EA201070272A1 (ru) 5-членное гетероциклическое соединение
ES2648223T3 (es) Procedimiento de preparación de (R)-5-(2-aminoetil)-1-(6, 8-difluorocroman-3-il)-1, 3-dihidroimidazol-2-tiona
ES2565087T3 (es) Procedimiento de preparación de derivados de 1-alquiltetrazolil oxima 5-sustituidos
FR2925328B1 (fr) Utilisation d'un hydrolysat de kamut en tant que principe actif activateur de la synthese des aquaporines